|
|
Vaccine Detail
|
Liposomal Diphtheria Toxoid331-345 Epitope-MUC1 Glycopeptide Vaccine with alpha-GalCer |
| Vaccine Information |
- Vaccine Name: Liposomal Diphtheria Toxoid331-345 Epitope-MUC1 Glycopeptide Vaccine with alpha-GalCer
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1; diptheria toxoid (Du et al., 2024)
-
Adjuvant:
alpha-GalCer (Du et al., 2024)
- Immunization Route: Intraperitoneal injection (i.p.)
- Description: A fully synthetic liposomal conjugate vaccine containing tumor-associated MUC1 glycopeptide covalently conjugated with a diphtheria toxoid-derived T-helper epitope (DT331-345, sequence: QSIALSSLMVAQAIP), adjuvanted with natural killer T (NKT) cell agonist alpha-galactosylceramide ((alpha)GalCer), and encapsulated in liposomes. Vaccination with DT-MUC1+(alpha)GalCer may stimulate both humoral and cellular immune responses against tumor cells expressing MUC1 antigen. The DT331-345 T-helper epitope facilitates CD4+ T cell activation and promotes IgM to IgG class switching, while (alpha)GalCer activates NKT cells to enhance downstream immune responses, together synergistically enhancing MUC1-specific immunity, resulting in a 189-fold increase in anti-MUC1 IgG antibody titers compared to MUC1+(alpha)GalCer and 3-fold compared to DT-MUC1 alone, with CDC activity against MUC1-expressing tumor cells. The vaccine also induced potent cellular immune responses including CTL activity, and significant tumor growth inhibition of B16-MUC1 melanoma tumors in vivo. MUC1, a membrane-bound glycoprotein overexpressed and aberrantly glycosylated in various cancers including breast, colorectal, ovarian, lung, and prostate cancers, serves as the target antigen. The vaccine demonstrated a favorable safety profile with no significant adverse effects on major organs or liver and kidney function (Du et al., 2024).
|
| Host Response |
|
|
| References |
Du et al., 2024: Du JJ, Zhou SH, Liu J, Zhong XY, Zhang RY, Zhao WX, Wen Y, Su ZH, Lu Z, Guo J. Diphtheria Toxoid-Derived T-Helper Epitope and α-galactosylceramide Synergistically Enhance the Immunogenicity of Glycopeptide Antigen. ACS pharmacology & translational science. 2024; 7(12); 3889-3901. [PubMed: 39698257].
|
|
